therapies by two orders of magnitude from $10,000+/L to $100/L.

Our four-pillar deep technology platform integrates our market validated replacements for animal serum (FBS) and novel microcarriers with our POC's for A.I. driven robotic cellular biocomputers & A.I. tools for cellular product isolation, creation, & final therapy enhancing formulas.

​NouBio Inc eliminates the primary bottlenecks needed to scale commercial assets of cellular human longevity drugs & therapies by solving:

1. Prohibitive unit economics: Achieving the "holy grail" price points for mass market adoption.

2. Industrial scalability: From lab to industrial production.

3. Downstream friction: Removing hurdles consuming 40% of bio-manufacturing time.

4. Batch volatility: Stabilizing 300% price fluctuations & variability.

NouBio Inc replaces operational losses and prohibitive production costs with scalable, high margin, commercial assets for all of cell-based biomanufacturing.

At a potential $10/L cost floor, NouBio Inc converts bio-manufacturing from a cost-prohibitive laboratory struggle into a high-margin industrial powerhouse.

NouBio Inc raised venture capital investment from Big Idea Ventures & angels.

NouSerum Commercial Validation*:

-Tested by over 30 users in 1 year for different cell-based industries -Has 300 serum proteins found in FBS -GRAS category (FDA) -No GMOs -Powder -Antimicrobial

*GMP compliant product launch in 2026

Future products:

-Cost-effective, bio-degradable microcarriers with no need to remove cells in bioreactors.

-AI driven robotic cellular biocomputer to replace bioreactors.

-AI formulas for enhanced cell-based products.